Stock listing
Dusseldorf:CUP Chugai Pharmaceutical Co., Ltd. Aktie
German listing (Dusseldorf) of Chugai Pharmaceutical Co., Ltd. · home listing Tokyo:4519
Follow Chugai Pharmaceutical Co., Ltd. into a list and get an email when it puts out news.
Share price · DUS:CUP
€39.61 EUR -1.17 (-2.9%)
Close on Nov 20, 2026
- Day range
- €39.61 – €40.58 EURNov 20, 2026
- Market cap
- €53.48B EURAt the close on Nov 20, 2026 · price × 1.35B shares outstanding
- 52-week range
- €33.42 – €57.10 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €0 EURMedian day 0 shares · 57 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| OTC:CHGCY | $22.26 USD | -0.20 (-0.9%) | 218,409 | $22.81 | $22.81 | $22.01 | $22.46 | Close on Nov 20, 2026 |
| OTC:CHGCF | $44.81 USD | +0.488 (+1.1%) | 561 | $44.81 | $44.81 | $44.81 | $44.32 | Close on Nov 20, 2026 |
| Frankfurt:CUP | €40.51 EUR | -0.67 (-1.6%) | — | €40.54 | €40.65 | €40.51 | €41.18 | Close on Nov 20, 2026 |
| Munich:CUP | €40.08 EUR | -1.67 (-4.0%) | — | €40.64 | €40.64 | €40.08 | €41.75 | Close on Nov 20, 2026 |
| Dusseldorf:CUP | €39.61 EUR | -1.17 (-2.9%) | — | €40.09 | €40.58 | €39.61 | €40.78 | Close on Nov 20, 2026 |
| Frankfurt:CUP0 | €19.50 EUR | -0.40 (-2.0%) | — | €19.50 | €19.50 | €19.50 | €19.90 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · DUS:CUP · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €38.68 | -0.654 | -1.7% | €38.71 | €38.83 | €38.67 | 0 | |
| €39.33 | +0.982 | +2.6% | €39.75 | €40.53 | €38.69 | 0 | |
| €38.35 | +0.233 | +0.6% | €38.57 | €38.71 | €38.19 | 0 | |
| €38.12 | +0.266 | +0.7% | €38.03 | €38.76 | €37.83 | 0 | |
| €37.85 | -0.684 | -1.8% | €38.15 | €38.39 | €37.83 | 0 | |
| €38.54 | +1.043 | +2.8% | €37.58 | €38.74 | €37.47 | 0 | |
| €37.49 | -0.131 | -0.3% | €37.56 | €37.64 | €36.98 | 0 | |
| €37.62 | -0.716 | -1.9% | €37.62 | €37.84 | €37.22 | 0 | |
| €38.34 | -0.364 | -0.9% | €37.84 | €38.37 | €37.82 | 0 | |
| €38.70 | +0.389 | +1.0% | €39.13 | €39.30 | €38.70 | 0 | |
| €38.32 | +1.035 | +2.8% | €38.28 | €38.46 | €38.05 | 0 | |
| €37.28 | +0.909 | +2.5% | €37.32 | €37.73 | €36.80 | 0 | |
| €36.37 | +0.47 | +1.3% | €36.16 | €36.81 | €36.14 | 0 | |
| €35.90 | +1.019 | +2.9% | €35.86 | €36.49 | €35.27 | 0 | |
| €34.88 | -0.222 | -0.6% | €34.88 | €34.89 | €34.88 | 0 | |
| €35.10 | -0.255 | -0.7% | €35.11 | €35.11 | €35.10 | 0 | |
| €35.36 | +1.353 | +4.0% | €35.34 | €35.39 | €35.33 | 0 | |
| €34.01 | -0.619 | -1.8% | €34.08 | €34.56 | €33.54 | 0 | |
| €34.63 | +0.911 | +2.7% | €34.70 | €35.02 | €34.63 | 0 | |
| €33.71 | -0.043 | -0.1% | €33.71 | €33.71 | €33.71 | 0 | |
| €33.76 | -0.166 | -0.5% | €33.76 | €33.77 | €33.55 | 0 | |
| €33.92 | -0.231 | -0.7% | €33.97 | €34.30 | €33.68 | 0 | |
| €34.15 | +0.063 | +0.2% | €34.11 | €34.22 | €34.05 | 0 | |
| €34.09 | +0.181 | +0.5% | €34.09 | €34.19 | €34.04 | 0 | |
| €33.91 | +0.482 | +1.4% | €34.21 | €34.47 | €33.77 | 0 | |
| €33.43 | -1.181 | -3.4% | €33.53 | €34.48 | €33.43 | 0 | |
| €34.61 | +0.083 | +0.2% | €33.96 | €34.83 | €33.47 | 0 | |
| €34.53 | +0.859 | +2.6% | €34.54 | €34.54 | €34.51 | 0 | |
| €33.67 | -1.476 | -4.2% | €33.77 | €34.00 | €33.42 | 0 | |
| €35.14 | -1.458 | -4.0% | €35.14 | €35.15 | €35.14 | 0 | |
| €36.60 | +0.627 | +1.7% | €36.55 | €36.61 | €36.54 | 0 | |
| €35.97 | -1.522 | -4.1% | €36.04 | €36.66 | €35.95 | 0 | |
| €37.50 | +0.33 | +0.9% | €37.46 | €37.54 | €36.99 | 0 | |
| €37.17 | +0.128 | +0.3% | €36.91 | €37.24 | €36.67 | 0 | |
| €37.04 | +0.17 | +0.5% | €37.12 | €37.46 | €36.67 | 0 | |
| €36.87 | -0.346 | -0.9% | €36.95 | €37.07 | €36.85 | 0 | |
| €37.21 | +1.354 | +3.8% | €37.17 | €37.72 | €36.95 | 0 | |
| €35.86 | -0.275 | -0.8% | €35.70 | €36.06 | €35.52 | 0 | |
| €36.14 | +0.507 | +1.4% | €36.16 | €36.16 | €36.14 | 0 | |
| €35.63 | +0.447 | +1.3% | €36.09 | €36.24 | €35.55 | 0 | |
| €35.18 | +0.067 | +0.2% | €35.21 | €35.32 | €34.82 | 0 | |
| €35.11 | -0.731 | -2.0% | €35.13 | €35.15 | €35.11 | 0 | |
| €35.85 | -0.353 | -1.0% | €35.89 | €35.97 | €35.67 | 0 | |
| €36.20 | -0.273 | -0.7% | €36.30 | €36.30 | €36.05 | 0 | |
| €36.47 | -0.691 | -1.9% | €36.45 | €36.53 | €36.30 | 0 | |
| €37.16 | -0.641 | -1.7% | €37.01 | €37.21 | €36.70 | 0 | |
| €37.80 | +0.93 | +2.5% | €37.47 | €37.84 | €37.25 | 0 | |
| €36.87 | -0.088 | -0.2% | €36.65 | €37.24 | €36.37 | 0 | |
| €36.96 | +0.432 | +1.2% | €37.10 | €37.42 | €36.86 | 0 | |
| €36.53 | -0.875 | -2.3% | €36.80 | €36.87 | €36.32 | 0 | |
| €37.40 | +0.302 | +0.8% | €37.42 | €38.20 | €37.05 | 0 | |
| €37.10 | -0.587 | -1.6% | €37.10 | €37.29 | €36.62 | 0 | |
| €37.69 | +0.476 | +1.3% | €37.82 | €37.94 | €37.68 | 0 | |
| €37.21 | +0.147 | +0.4% | €36.91 | €37.39 | €36.76 | 0 | |
| €37.07 | -0.733 | -1.9% | €37.15 | €37.15 | €36.85 | 0 | |
| €37.80 | -0.026 | -0.1% | €37.68 | €37.82 | €37.51 | 0 | |
| €37.83 | +0.816 | +2.2% | €38.06 | €38.06 | €37.31 | 0 |
Splits
1 split · DUS:CUP · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 3-for-1 | Split |
- Ticker
- Dusseldorf:CUP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news release · Oct 27, 2026
Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS)
Latest earnings call · Jul 24, 2026
Chugai Pharmaceutical (Tokyo:4519) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Oct 27, 2026
Q3 2026 Earnings Presentation
Earnings · 32 slides
Latest news
Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS)
Oct 27, 2026
Closed €38.34 (-0.9%) on Oct 27, 2026
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the nine months ended September 30, 2026)
Oct 27, 2026
Closed €38.34 (-0.9%) on Oct 27, 2026
F. Hoffmann-La Roche Announces Third Quarter Sales 2026
Oct 22, 2026
Closed €37.28 (+2.5%) on Oct 22, 2026
Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA
Sep 28, 2026
Closed €35.14 (-4.0%) on Sep 28, 2026
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors
Sep 9, 2026
Closed €35.85 (-1.0%) on Sep 9, 2026
Chugai and GSK Sign Exclusive License Agreement for Anti-Dengue Virus Antibody AID351
Aug 18, 2026
Closed €35.98 (-3.7%) on Aug 18, 2026
Chugai Announces 2026 2nd Quarter Results
Jul 27, 2026
Closed €35.83 (-7.4%) on Jul 27, 2026
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026)
Jul 24, 2026
Closed €38.71 (+2.0%) on Jul 24, 2026
F. Hoffmann-La Roche Announces Half Year Results 2026
Jul 23, 2026
Closed €37.95 (-3.4%) on Jul 23, 2026
Chugai Files New Drug Application in Japan for Sparsentan for the Treatment of IgA Nephropathy
Jun 22, 2026
Closed €40.16 (-1.0%) on Jun 22, 2026
Chugai Pharmaceutical Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 25 in the last 12 months · 31 in all · newest Oct 27, 2026 · oldest 2025
- Calls
- 9 calls with a replay · 9 with a transcript · latest Jul 24, 2026
- Decks
- 107 decks · latest Oct 27, 2026
Where Chugai Pharmaceutical Co., Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Tokyo:4519 中外製薬 · Home listing | Tokyo | Japan | JPY |
| OTC:CHGCY | OTC | United States | USD |
| OTC:CHGCF | OTC | United States | USD |
| gettex:CUP | gettex | Germany | EUR |
| Frankfurt:CUP | Frankfurt | Germany | EUR |
| Tradegate:CUP | Tradegate | Germany | EUR |
| LS Exchange:857216 | LS Exchange | Germany | EUR |
| Lang & Schwarz:857216 | Lang & Schwarz | Germany | EUR |
| BMV:4519N | BMV | Mexico | MXN |
| Munich:CUP | Munich | Germany | EUR |
| Stuttgart:CUP | Stuttgart | Germany | EUR |
| Hamburg:CUP | Hamburg | Germany | EUR |
| Dusseldorf:CUP · This page | Dusseldorf | Germany | EUR |
| gettex:CUP0 | gettex | Germany | EUR |
| Hanover:CUP | Hanover | Germany | EUR |
| BIVA:4519N | BIVA | Mexico | MXN |
| Frankfurt:CUP0 | Frankfurt | Germany | EUR |
| Munich:CUP0 | Munich | Germany | EUR |
Team and board
Officers
| Officer | Role |
|---|---|
| Osamu Okuda | Representative Director, President & CEO |
| Iwaaki Taniguchi | Director, Executive Vice President & CFO |
| Hitoshi Iikura | Director, Executive Vice President |
| Boris L. Zaïtra | Head of Corporate Business Development of Roche |
Board
| Director | Role |
|---|---|
| Boris L. Zaïtra | Head of Corporate Business Development of Roche |
| Hitoshi Iikura | Director, Executive Vice President |
| Iwaaki Taniguchi | Director, Executive Vice President & CFO |
| Masayoshi Higuchi | Audit & Supervisory Board Member (full-time) |
| Osamu Okuda | Representative Director, President & CEO |
| Shigehiro Yamada | Audit & Supervisory Board Member (full-time) |
| Teresa A. Graham | Director |
| Thomas Schinecker | Director |
Events
| Call | When | Status |
|---|---|---|
| Chugai Pharmaceutical (Tokyo:4519) Q2 2026 Earnings Call | Fri, Jul 24, 2026 · 3:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q1 2026 Earnings Call | Fri, Apr 24, 2026 · 5:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q4 2025 Earnings Call | Thu, Jan 29, 2026 · 3:30 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q3 2025 Earnings Call | Sat, Oct 25, 2025 · 5:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q2 2025 Earnings Call | Thu, Jul 24, 2025 · 4:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q4 2024 Earnings Call | Thu, Jan 30, 2025 · 3:30 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q3 2024 Earnings Call | Fri, Oct 25, 2024 · 5:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q2 2024 Earnings Call | Wed, Jul 24, 2024 · 4:00 AM ET | Replay |
| Chugai Pharmaceutical (Tokyo:4519) Q1 2024 Earnings Call | Wed, Apr 24, 2024 · 5:00 AM ET | Replay |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 32 slides | Oct 27, 2026 |
| Q3 2026 Earnings Presentation | Earnings | 32 slides | Oct 27, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 34 slides | Jul 24, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 34 slides | Jul 24, 2026 |
| Technical Presentation (June 2026) | Technical | 45 slides | Jun 17, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 34 slides | Apr 24, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 53 slides | Jan 29, 2026 |
| Q2 2025 Earnings Presentation | Earnings | 47 slides | Jul 24, 2025 |
| souzoulabo slide | 6 slides | February 2025 | |
| FY2024 Earnings Presentation | Earnings | 56 slides | Jan 30, 2025 |
Show 50 decks
This page holds 50 of 107 decks. Open Decks
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the nine months ended September 30, 2026) | Oct 27, 2026 | Results | Tokyo Stock Exchange |
| Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS) | Oct 27, 2026 | Results | Tokyo Stock Exchange |
| F. Hoffmann-La Roche Announces Third Quarter Sales 2026 | Oct 22, 2026 | Other filings | Tokyo Stock Exchange |
| Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA | Sep 28, 2026 | Other filings | Tokyo Stock Exchange |
| CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026) | Jul 24, 2026 | Interim report | Tokyo Stock Exchange |
| F. Hoffmann-La Roche Announces Half Year Results 2026 | Jul 23, 2026 | Interim report | Tokyo Stock Exchange |
Cap table
Built by 6ix from Chugai Pharmaceutical Co., Ltd.’s releases
- Common shares
- 1,679,057,667
- Fully diluted
- 1,679,057,667
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,679,057,667 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,679,057,667 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Boris L. Zaïtra | Head of Corporate Business Development of Roche · Since at least Mar 27, 2026 |
| Hitoshi Iikura | Director, Executive Vice President · Since at least Mar 27, 2026 |
| Iwaaki Taniguchi | Director, Executive Vice President & CFO · Since at least Mar 27, 2026 |
| Masayoshi Higuchi | Audit & Supervisory Board Member (full-time) · Since at least Nov 5, 2026 |
| Osamu Okuda | Representative Director, President & CEO · Since at least Sep 9, 2026 |
| Shigehiro Yamada | Audit & Supervisory Board Member (full-time) · Since at least Nov 5, 2026 |
| Teresa A. Graham | Director · Since at least Mar 27, 2026 |
| Thomas Schinecker | Director · Since at least Mar 27, 2026 |
Log in to ask 6ix AI your own questions about Chugai Pharmaceutical Co., Ltd.